Specialty Pharmacy

The 5-year survival rate for patients with exon 20 insertion EFGR mutation is 8% in the frontline setting, worse than the survival rate of the 2 most common types of EGFR mutations in patients with advanced or metastatic non-small cell lung cancer.

Drug shortages have led to increased use of compounding pharmacy.

Quality standards and national regulation help to establish its role as medicine.

Evidence remains limited for specific therapies to treat the disease, but new clinical trials are ongoing.

Those infected with HIV could have experienced more hardships during the peak of the pandemic and could suffer more challenges with the lack of resources post-pandemic.

Express Scripts recently announced the addition of 3 Humira biosimilars to its main formulary.

Analyzing the patent and trademark challenges faced by 503A compounding pharmacies.

Albumin is a cost-effective predictor of intravenous immunoglobulin-resistance in young patients with Kawasaki disease.

Institutional review boards and ethics committees have seen it as their main task in the past few decades to protect children from questionable studies; however, they are faced with a new challenge with pediatric drug development.

COVID-19 is helping to shape current pharmacy practice, including increased vaccinations, access to care, and better interactions with patients.

More than half of the patients prescribed oral anticancer agents report persistent moderate-to-severe symptoms, despite receiving counseling on adverse effect management.

Valoctocogene roxaparvovec-rvox (Roctavian; BioMarin) is a one-time gene therapy product administered as a single dose by intravenous infusion for hemophilia A.

Researchers noted that the therapy remains risky, owing to the substantial immunosuppressive and cytopenic effects of the trial protocol and the risks that immune-cell manipulation carries.

McKesson ideaShare 2023 recognized pharmacy technicians with a technician-focused continuing education (CE) session, roundtable, and honorary reception.

Somatrogon-ghla (Ngenla; Pfizer Inc, OPKO Health Inc) is a subcutaneous injection that is administered once weekly via a device allowing for titration based on patients’ needs.

During the pandemic, many community pharmacists also gained the authority to provide routine vaccinations for child populations.

As part of the approval condition, the FDA is requiring Sarepta Therapeutics to complete a clinical study to confirm the drug’s benefit in motor and physical functions.

Mama Village Rx & Wellness cares for Mamaroneck community, owner considers patients like family.

Imposing the FDA on-label/off-label framework on administratively defined "children" resulted in a regulatory demand for pediatric studies that had no basis in clinical medicine, with the exception of the small group of preterm newborns.

Despite having a lower cost of development than the innovator, romiplostim biosimilar has comparable efficacy and safety in patients with chronic immune thrombocytopenia.

Denise Scarpelli, PharmD, MBA, discussed her presentation at the ASHP 2023 Summer Meeting.

Expert provides numerous resources to learn more about the Centers for Medicare & Medicaid Services Enhancing Oncology Model.

Denise Scarpelli, PharmD, MBA, discussed her presentation at the ASHP 2023 Summer Meeting.

Neuromyelitis optica spectrum disorder is an autoimmune disease characterized by severe attacks of optic neuritis and/or myelitis, leading to possible visual loss, paralysis, cognitive impairment, sensory deficits, bladder dysfunction, and even mortality.

Previously, upadacitinib improved symptoms through 2 years in the SELECT-PsA 1 trial for those with psoriatic arthritis with prior inadequate response or intolerance to ≥1 non-biologic disease-modifying antirheumatic drug.

Real-world metrics demonstrate that using health-system specialty pharmacies (HSSPs) means everyone wins: health systems, clinicians, and patients.

Upadacitinib 15 mg once daily had a better clinical response compared to adalimumab 40 mg every other week at 12 weeks in 3-year follow-up data among patients with rheumatoid arthritis.

Pharmacogenomic testing in combination with therapeutic drug monitoring can be a cost effective and efficient way to advance psychiatric drug therapy.

As more becomes known about Crohn disease, treatment modalities have evolved with biologic monoclonal antibodies becoming a key part of guideline- and evidence-based medicine.

Research has shown these programs can increase the number of patients who can access targeted treatments.